Фенофибрат в лечении атерогенных дислипопротеидемий и атеросклероза

1. Adkins JC., Faulds D. Micronised fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1995;54 (4):615-633.

2. Перова НВ. Гиполипидемическая терапия при метаболическом синдроме. «Кардиология-99» Изд-во Мораг-Экспо. Москва; 1999:39-48.

3. Chapman MJ. Fibrates in 2003:therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis. 2003;171:1-13

4. Belalcazar LM, Ballantyne CM. Defining specific goals of therapy in treating dyslipidaemia in the patient with low high-density lipoprotein cholesterol. Prog Cardiovasc Dis. 1998;41:151-174.

5. Committee of Principal Investigators. A cooperative trial in the prevention of ischemic heart disease using clofibrate. Br Heart J. 1978;40:1069-1118.

6. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol: final mortality follow-up. Lancet. 1984;ii:600-604.

7. Frick MH, Elo MO, Haapa K. et al. Helsinki Heart Study:primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, Changes in risk factors and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.

8. Rubins HB, Robins SJ, Collins D, et al. Gemfibrosil for the secondary prevention of coronary heart disease in men with low lewels of hogh-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.

9. The BIP Study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease . The bezafibrate infarction prevention (BIP) study. Circulation. 2000;102:21-27.

10. Erricsson CG, Hamsted A, Nilsson J. et al. Angiographic assessment of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.

11. Bunte T, Hahmann HW, Hellwig N. et al. Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients. Atherosclerosis. 1993;98:127-138.

12. Schoonjans K, Staeles B, Auwex J. Role of the peroxisome proliferator-activated receptors (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37:907-925.

13.

14. Neve BR, Fruchart JC, Staels B. Role of peroxisome proliferators-activated receptors (PPAR)in atherosclerosis. Biochem Pharmacol. 2000;60(8):1245-1250

15. BarbierO, Pineda Torra J, Dugay Y. et al. Pleiotropic actions of peroxisome proliferators-activated receptors in lipid metabolism and atherosclerosis. Atheroscler Thromb Vasc Biol. 2002;22:717-728.

16. Fruchart JC, Duries P, Staels B. Peroxisome proliferators-activated receptor- activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999;10(3):245-257. Review.

17. Fazio S, Luton MF. The role of fibrates in managing hyperlippdemia:mechanism of action and clinical efficacy. Curr Atherosclerosis Rep. 2004;6:148-157]

18. Staeles B, Vu-Dac N, Kosykh V. et.al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase:a potential mechanism for the hypolipidemic action of fibrates. J Clin Invest. 1995;95:705-712.

19. Dues H, Lefebvre B, Poulain P. et al. Regulation of human apo A-1 by gemfibrozil and fenofibrate rthrough selective peroxisome proliferators-activated receptor-modulation. Atherosclerosis Thromb Vasc Biol. 2005;25(3):585-591.

20. Guerin M, Bruckert E, Dolphin P et. al. Fenofibrate reduces cholesterol ester transfer from HDL to VLDL and normalises the atherogenic dense LDL particle in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996;16:763-772.

21. Gardner CD, Fortmann SP, Krauss RM. Assotion of small LDL particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.

22. Stampfer MJ, Krauss RM Ma J. et al. A prospective study of triglyceride level, LDL particle diameter, and risk of myocardial infarction. J Am Med Assoc. 1996;276:882-888.

23. Lamarche B, Fchernof A, Moorjani S. et al. Small, dense LDL particles as a predictor for the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.

24. Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-1069.

25. Miller BD, Alderman EL, Haskel WL. еt al. Predominance of dense LDL particles predicts angiographic benefit of therapy in Stanford Coronary Risk Intervention Project. Circulation 1996;i:2146-2153.

26. Despres JP, Lemieux I, Robins SJ. Role of fibric acid dervatives in the management of risk factors for coronary heart disease. Drugs 2004;64 (19) :2177-2198.

27. Fruchart JC, Brewer HB, Leitersdorf E. Consesus for use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998;81:912-916.

28. Lemieux I, Laperriere L, Dzavik V. et al. A 16-week genofibrate treatment increases LDL particle size in type IIa dyslipidemic patients. Atherosclerosis 2002;162 (2):363-371.

29. Перова Н.В. Нарушения липидного обмена, их диагностика и коррекция. В кн. Кардиология. Руководство для врачей. Под ред. Оганова Р.Г, Фоминой И.Г., М.:Медицина, 2004:54-101.

30. Kornitzer M, Dramax M, Vanderbrock MD. et al. Efficacy and tolerance of 200 mg micronised fenofibrate alministered over a 6-month period in hyperlipidemic patients:an open Belgian multicenter study. Atherosclerosis 1994;110 (Suppl):S49-S54.

31. Kirchgassler KU, Schmitz H, Bach G. Effectivenes and tolerability of 12-week treatment with micronized fenofibrate 200 mg in a drug - monitoring programme involving 9884 patients with dyslipidemia. Clin Drug Invest 1998;15:197-204.

32. Poulter N. The impact of micronized fenofibrate on lipid subfractions and on reaching HDL-target levels in 7.098 patients with dyslipidemia. Brit J Cardiol 1999;6:682-685.

33. Friedwald WT., Levy RI., Fredrikson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.

34. Оганов Р.Г., Перова Н.В. Питание в лечении атерогенных дислипопротеидемий. Кардиология, 1990,30(5):5-7.

35. Оганов Р.Г., Доборджгенидзе Л.М., Перова Н.В., Жуковский Г.С. Диетотерапия атерогенных дислипопротеидемийю Кардиология, 1990;30 (5):115-123.

36. Pascal M, Richard B, Cao Danh H. Effect of fenofibrate on HMG CoA reductase activity and LDL receptor in liver. Int. Symp. on Cholesterol Control and Cardiovasculer Disease:Prevention and Therapy. Milan;1987:p.223-228.

37. Scheider A, Stange E, Ditschuneit H, Ditschuneit H. Fenofibrate treatment ingidits HMG CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. Atherosclerosis 1983;56:237-262.

38. Pascal M, Richard B, Cao Danh H. Effect of fenofibrate on HMG CoA reductase activity and LDL receptor in liver. Int. Symp. on Cholesterol Control and Cardiovasculer Disease:Prevention and Therapy. Milan;1987:p.223-228.

39. Scheider A, Stange E, Ditschuneit H, Ditschuneit H. Fenofibrate treatment ingidits HMG CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. Atherosclerosis 1983;56:237-262.

40. Weisweiler P, Low-dose colestipol plus fenofibrate:effects on plasma lipoproteins, lecithin:cholesterol acyltransferase and postheparin lipases in familial hypercholesterolemia. Metabolism 1989;38 (3):271-274.